Product category:
Laboratory and scientific manufacturing services
News Release from: Novacta Biosystems
Edited by the Laboratorytalk Editorial
Team on 16 January 2008
Millions to target C Difficile
infections
Wellcome Trust, the UK's largest medical research charity, has awarded Novacta Biosystems £3.5 million as part of the Trust's Strategic Translational Award programme
Novacta will use the award to progress development of a drug which, it is hoped, will help combat hospital-based Clostridium difficile (C difficile) infections C difficile infections (CDIs) are a growing and serious problem and have, for example, been associated with twice as many deaths in UK hospitals last year as MRSA
This article was originally published on Laboratorytalk on 24 Feb 2003 at 8.00am (UK)
Related stories
First spinal study of bone substitute
Study will measure performance of synthetic bone graft substitute in 30 patients undergoing spinal fusion for degenerative disc disease
Acquisition creates global CRO
Advanced Clinical Sciences becomes a global player in clinical research with the takeover of a Swiss CRO called CRC
Cases of C difficile infections, which occur in the lower digestive tract, rose by 22 per cent in the past year and affected more than 15,500 people over 65 in the first quarter of 2007.
New anti-infective drugs are needed to target C difficile without depleting other beneficial bacteria in the gut.
Novacta is developing novel, naturally-derived products known as 'lantibiotics' as potential drugs for treating hospital acquired infections caused by C difficile.
Early preclinical data show promise for an effective treatment for CDI, acting selectively to kill C difficile with less disturbance of normal gut bacteria than seen with existing drugs.
Novacta will use the Wellcome Trust Strategic Translational award to progress its preclinical drug candidates into human clinical studies.
Ted Bianco, director of technology transfer at the Wellcome Trust, said: "It is ironic that the current rise in C difficile infections owes much to the widespread use of broad spectrum antibiotics.
"We need to be smarter in how we deploy our existing medicines and how we develop new treatments.
"Novacta should be applauded for its efforts to move away from carpet bombing our microbial flora in favour of precision targeting of the C difficile bacterium".
Mike Dawson, Novacta's chief scientific officer, commented: "We are encouraged by early preclinical results which show potential for a much more selective approach to treat CDI.
"The Trust's support will enable us to complete preclinical development and to conduct a Phase I clinical trial to establish safety and tolerability in humans".
Tony Sedgwick, Novacta's chief executive officer, commented: 'We are delighted that the Wellcome Trust has recognised our work in the area of lantibiotic drugs for the treatment of CDI.
"We are now positioned to evaluate the clinical potential of our programme, while we continue to build our product pipeline for other therapeutic indications.".
• Novacta Biosystems: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
